Search alternatives:
μ decrease » _ decreased (Expand Search), _ decreases (Expand Search), a decreased (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
c decrease » c decreased (Expand Search), rc decreased (Expand Search), _ decreased (Expand Search)
50 μ » 10 μ (Expand Search), 5 μ (Expand Search)
50 a » 50 c (Expand Search), 5 a (Expand Search), 0 a (Expand Search)
30 c » 37 c (Expand Search), 3 c (Expand Search), 30 _ (Expand Search)
μ decrease » _ decreased (Expand Search), _ decreases (Expand Search), a decreased (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
c decrease » c decreased (Expand Search), rc decreased (Expand Search), _ decreased (Expand Search)
50 μ » 10 μ (Expand Search), 5 μ (Expand Search)
50 a » 50 c (Expand Search), 5 a (Expand Search), 0 a (Expand Search)
30 c » 37 c (Expand Search), 3 c (Expand Search), 30 _ (Expand Search)
-
1
-
2
-
3
-
4
-
5
TUDCA decreases ER stress in HOX neonatal rat lungs.
Published 2022“…(<b>C</b>) In IHC stain, P-IRE1α levels are decreased (40.8±3.5 A.U. …”
-
6
-
7
-
8
-
9
-
10
Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades
Published 2022“…<i>N</i>-(4-Bromophenyl)-4-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine <b>4f</b>, <i>N</i>-(4-chlorophenyl)-4,6-bis(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-1,3,5-triazin-2-amine <b>5c</b>, and 4,6-<i>bis</i>(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(4-methoxyphenyl)-1,3,5-triazin-2-amine <b>5d</b> showed promising activity against these cancer cells: <b>4f</b> [(IC<sub>50</sub> = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; <b>5d</b> [(IC<sub>50</sub> = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and <b>5c</b> [(IC<sub>50</sub> = 2.29 ± 0.92 μM (MCF-7)]. …”
-
11
Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades
Published 2022“…<i>N</i>-(4-Bromophenyl)-4-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine <b>4f</b>, <i>N</i>-(4-chlorophenyl)-4,6-bis(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-1,3,5-triazin-2-amine <b>5c</b>, and 4,6-<i>bis</i>(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(4-methoxyphenyl)-1,3,5-triazin-2-amine <b>5d</b> showed promising activity against these cancer cells: <b>4f</b> [(IC<sub>50</sub> = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; <b>5d</b> [(IC<sub>50</sub> = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and <b>5c</b> [(IC<sub>50</sub> = 2.29 ± 0.92 μM (MCF-7)]. …”
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20